COCP Stock Overview
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Cocrystal Pharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.51 |
52 Week High | US$3.29 |
52 Week Low | US$1.33 |
Beta | 1.35 |
1 Month Change | 1.40% |
3 Month Change | -4.43% |
1 Year Change | -39.60% |
3 Year Change | -89.69% |
5 Year Change | -95.17% |
Change since IPO | -99.38% |
Recent News & Updates
Recent updates
Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19
Oct 11Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21
Aug 15Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans
Aug 14Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK
Aug 08We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate
Mar 19Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth
Nov 19We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth
Aug 06Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants
Jun 14We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully
May 05Cocrystal Pharma updates on COVID-19 antiviral development programs
May 03Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%
Mar 13What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?
Jan 24Cocrystal sees 2021 cash burn of $800k a month
Jan 11Cocrystal Pharma to test CDI-45205 against coronaviruses
Dec 22Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?
Dec 20Shareholder Returns
COCP | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 1.0% | -0.6% | 1.0% |
1Y | -39.6% | 10.6% | 21.9% |
Price Volatility
COCP volatility | |
---|---|
COCP Average Weekly Movement | 7.1% |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 12 | Sam Lee | www.cocrystalpharma.com |
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection.
Cocrystal Pharma, Inc. Fundamentals Summary
COCP fundamental statistics | |
---|---|
Market cap | US$15.36m |
Earnings (TTM) | -US$17.98m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs COCP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
COCP income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$15.17m |
Gross Profit | -US$15.17m |
Other Expenses | US$2.82m |
Earnings | -US$17.98m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.77 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did COCP perform over the long term?
See historical performance and comparison